Recurrent Islet Cell Carcinoma Completed Phase 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0028802 (Recurrent Islet Cell Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00131911Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsTreatment